How causal inference concepts can guide research into the effects of climate on infectious diseases
Authors:
Laura Andrea Barrero Guevara,
Sarah C Kramer,
Tobias Kurth,
Matthieu Domenech de Cellès
Abstract:
A pressing question resulting from global warming is how infectious diseases will be affected by climate change. Answering this question requires research into the effects of weather on the population dynamics of transmission and infection; elucidating these effects, however, has proven difficult due to the challenges of assessing causality from the predominantly observational data available in ep…
▽ More
A pressing question resulting from global warming is how infectious diseases will be affected by climate change. Answering this question requires research into the effects of weather on the population dynamics of transmission and infection; elucidating these effects, however, has proven difficult due to the challenges of assessing causality from the predominantly observational data available in epidemiological research. Here, we show how concepts from causal inference -- the sub-field of statistics aiming at inferring causality from data -- can guide that research. Through a series of case studies, we illustrate how such concepts can help assess study design and strategically choose a study's location, evaluate and reduce the risk of bias, and interpret the multifaceted effects of meteorological variables on transmission. More broadly, we argue that interdisciplinary approaches based on explicit causal frameworks are crucial for reliably estimating the effect of weather and accurately predicting the consequences of climate change.
△ Less
Submitted 19 February, 2024;
originally announced February 2024.
IMPECCABLE: Integrated Modeling PipelinE for COVID Cure by Assessing Better LEads
Authors:
Aymen Al Saadi,
Dario Alfe,
Yadu Babuji,
Agastya Bhati,
Ben Blaiszik,
Thomas Brettin,
Kyle Chard,
Ryan Chard,
Peter Coveney,
Anda Trifan,
Alex Brace,
Austin Clyde,
Ian Foster,
Tom Gibbs,
Shantenu Jha,
Kristopher Keipert,
Thorsten Kurth,
Dieter Kranzlmüller,
Hyungro Lee,
Zhuozhao Li,
Heng Ma,
Andre Merzky,
Gerald Mathias,
Alexander Partin,
Junqi Yin
, et al. (11 additional authors not shown)
Abstract:
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2-3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silicomethodologies need to be improved to better select lead compounds that can proceed to later stages of the drug discovery protocol accelerating…
▽ More
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2-3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silicomethodologies need to be improved to better select lead compounds that can proceed to later stages of the drug discovery protocol accelerating the entire process. No single methodological approach can achieve the necessary accuracy with required efficiency. Here we describe multiple algorithmic innovations to overcome this fundamental limitation, development and deployment of computational infrastructure at scale integrates multiple artificial intelligence and simulation-based approaches. Three measures of performance are:(i) throughput, the number of ligands per unit time; (ii) scientific performance, the number of effective ligands sampled per unit time and (iii) peak performance, in flop/s. The capabilities outlined here have been used in production for several months as the workhorse of the computational infrastructure to support the capabilities of the US-DOE National Virtual Biotechnology Laboratory in combination with resources from the EU Centre of Excellence in Computational Biomedicine.
△ Less
Submitted 13 October, 2020;
originally announced October 2020.
